$DHR — BUY 📊

$DHR — BUY 📊 Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. 🎯 Q1 FY26 | Rev $6B | EPS $2.06 vs $1.94 🟢 | Margin 24.1% 💡 Consensus expects mid-single-digit EPS growth, but improving bioprocessing demand, China recovery, and operating leverage could drive high-single-digit growth and positive estimate revisions, leading to a re-rating from a compressed multiple back toward historical averages. 📉 Reward/Risk: 1.8:1 🏢 Business Quality: 9/10 - Best-in-class management (DBS), dominant life sciences and diagnostics platforms, high margins, strong FCF, disciplined capital allocation. Also in play: $CNC $HUM $UNH $CI $ELV $MCK

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.